Raising Health · 2026-03-09 · 52 min
Daisy Wolf speaks with Dr. Andrew Huberman, professor of neurobiology and ophthalmology at Stanford University and host of the Huberman Lab podcast. They discuss how the pandemic sparked a consumer health revolution, the emerging peptide and GLP landscape, what the science actually says about focus drugs, and the neurotechnologies Huberman believes will let us write to our own biology within the next five years. Resources: Follow Andrew Huberman on X: Follow Daisy Wolf on X: Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! Find a16z on X: Find a16z on LinkedIn: Listen to the a16z Show on Spotify: Listen to the a16z Show on Apple Podcasts: Follow our host: Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see . Hosted by Simplecast, an AdsWizz company.
AI, Healthcare, and 700 Million Patients | Nicolas Abad, Telepatía67 / 100Healthcare Will Benefit Most from AI | Julie Yoo on StartUp HealthRebuilding Behavioral Health’s Operating System with AIAI in Healthcare: The Leapfrog OpportunityAmbience CEO Nikhil Buduma on AI in Clinical Workflows